BridgeBio Pharma Inc. [BBIO] Stock trading around $9.29 per share: What’s Next?


BridgeBio Pharma Inc. [NASDAQ: BBIO] stock went on a downward path that fall over -15.78% on Tuesday, amounting to a one-week price decrease of less than -3.03%. The company report on July 26, 2022 that BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


– At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) was +1.52 cm/yr (p=0.02, n=11) and the responder rate was 64% in children 5 years and older1.

– Infigratinib was well-tolerated with no serious adverse events (SAE) and no discontinuations due to adverse events (AE) including in Cohort 5 (dose: 0.25 mg/kg once daily) participants dosed to date, with a median duration of follow-up of 48.1 weeks; only a limited number of AEs were assessed as related to study drug and all were Grade 1, the lowest level.

Over the last 12 months, BBIO stock dropped by -83.50%. The one-year BridgeBio Pharma Inc. stock forecast points to a potential upside of 60.75. The average equity rating for BBIO stock is currently 1.60, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $1.34 billion, with 145.88 million shares outstanding and 101.96 million shares in the current float. Compared to the average trading volume of 2.12M shares, BBIO stock reached a trading volume of 5942526 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on BridgeBio Pharma Inc. [BBIO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $23.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

SVB Leerink have made an estimate for BridgeBio Pharma Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 27, 2021. While these analysts kept the previous recommendation, Mizuho dropped their target price from $86 to $25. The new note on the price target was released on December 27, 2021, representing the official price target for BridgeBio Pharma Inc. stock. Previously, the target price had yet another raise to $75, while BofA Securities analysts kept a Buy rating on BBIO stock.

The Average True Range (ATR) for BridgeBio Pharma Inc. is set at 0.94, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 18.86.

BBIO Stock Performance Analysis:

BridgeBio Pharma Inc. [BBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.03. With this latest performance, BBIO shares gained by 0.54% in over the last four-week period, additionally sinking by -11.35% over the last 6 months – not to mention a drop of -83.50% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 49.97, with the RSI for the last a single of trading hit 46.73, and the three-weeks RSI is set at 51.23 for BridgeBio Pharma Inc. [BBIO]. The present Moving Average for the last 50 days of trading for this stock 8.27, while it was recorded at 10.03 for the last single week of trading, and 10.97 for the last 200 days.

Insight into BridgeBio Pharma Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and BridgeBio Pharma Inc. [BBIO] shares currently have an operating margin of -827.12 and a Gross Margin at +90.88. BridgeBio Pharma Inc.’s Net Margin is presently recorded at -806.90.

BridgeBio Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.90 and a Current Ratio set at 6.90.

BridgeBio Pharma Inc. [BBIO] Insider Position Details

There are presently around $1,580 million, or 98.00% of BBIO stock, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 31,060,971, which is approximately 0% of the company’s market cap and around 4.30% of the total institutional ownership; VIKING GLOBAL INVESTORS LP, holding 26,620,991 shares of the stock with an approximate value of $293.63 million in BBIO stocks shares; and VANGUARD GROUP INC, currently with $103.95 million in BBIO stock with ownership of nearly 0.99% of the company’s market capitalization.

Positions in BridgeBio Pharma Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 97 institutional holders increased their position in BridgeBio Pharma Inc. [NASDAQ:BBIO] by around 16,791,258 shares. Additionally, 111 investors decreased positions by around 15,242,356 shares, while 28 investors held positions by with 111,249,315 shares. The mentioned changes placed institutional holdings at 143,282,929 shares, according to the latest SEC report filing. BBIO stock had 47 new institutional investments in for a total of 3,597,721 shares, while 51 institutional investors sold positions of 6,806,076 shares during the same period.